How to buy aTyr Pharma stock (LIFE)

aTyr Pharma is a biotechnology business based in the US. aTyr Pharma shares (LIFE) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.00 – the same closing value as a week prior. aTyr Pharma employs 56 staff and has a trailing 12-month revenue of around $588,000.

Our top picks for where to buy aTyr Pharma stock

Buy aTyr Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

aTyr Pharma stock price (NASDAQ: LIFE)

Use our graph to track the performance of LIFE stocks over time.

aTyr Pharma shares at a glance

• Key figures

Information last updated 2024-08-04.

Latest market close	$0.00
52-week range	$1.08 - $2.15
50-day moving average more info button	$1.76
200-day moving average more info button	$1.59
Wall St. target price	$24.60
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.88

Is it a good time to buy aTyr Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

aTyr Pharma price performance over time

Historical closes compared with the close of $0 from 2024-06-18

1 week (2024-10-19)	N/A
1 month (2024-09-26)	N/A
3 months (2024-07-26)	N/A
6 months (2024-04-30)	-100.00%

1 year (2023-10-30)	-100.00%
2 years (2022-10-28)	-100.00%
3 years (2021-10-26)	N/A
5 years (2019-10-30)	3.56

aTyr Pharma financials

Revenue TTM	$588,000
Gross profit TTM	$-32,422,000
Return on assets TTM	-29.37%
Return on equity TTM	-55.61%
Profit margin	0%
Book value	$1.24
Market Capitalization more info button	$131.1 million

TTM: trailing 12 months

aTyr Pharma share dividends

We're not expecting aTyr Pharma to pay a dividend over the next 12 months.

Have aTyr Pharma's shares ever split?

aTyr Pharma's shares were split on a 1:14 basis on 30 June 2019 . So if you had owned 14 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your aTyr Pharma shares – just the quantity. However, indirectly, the new 1300% higher share price could have impacted the market appetite for aTyr Pharma shares which in turn could have impacted aTyr Pharma's share price.

aTyr Pharma share price volatility

Over the last 12 months, aTyr Pharma's shares have ranged in value from as little as $1.0801 up to $2.15. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while aTyr Pharma's is 1.188. This would suggest that aTyr Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

aTyr Pharma overview

aTyr Pharma, Inc. , a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co. , Ltd. for the development and commercialization of efzofitimod for ILDs in Japan.

Frequently asked questions

null
What percentage of aTyr Pharma is owned by insiders or institutions?
Currently 2.618% of aTyr Pharma shares are held by insiders and 61.688% by institutions. How many people work for aTyr Pharma?
Latest data suggests 56 work at aTyr Pharma. When does the fiscal year end for aTyr Pharma?
aTyr Pharma's fiscal year ends in December. Where is aTyr Pharma based?
aTyr Pharma's address is: 10240 Sorrento Valley Road, San Diego, CA, United States, 92121 What is aTyr Pharma's ISIN number?
aTyr Pharma's international securities identification number is: US0021202025 What is aTyr Pharma's CUSIP number?
aTyr Pharma's Committee on Uniform Securities Identification Procedures number is: 002120202